Bimekizumab

(Bimzelx®)

Bimekizumab

Drug updated on 4/16/2024

Dosage FormInjection (subcutaneous; 160 mg/mL in a single-dose prefilled syringe or single-dose prefilled autoinjector)
Drug ClassHumanized interleukin-17A and F antagonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated, with no liability accepted for reliance on it. Learn more.

  • Bimekizumab (Bimzelx) demonstrates a highly favorable profile for efficacy across multiple clinical endpoints in both psoriatic arthritis and plaque psoriasis, showing superior performance in achieving minimal disease activity, PASI 90, and PASI 100 across various subgroups.
  • Eight studies were reviewed to derive insights about the drug's safety, efficacy, and comparisons with other treatments for moderate-to-severe plaque psoriasis.
  • Compared to other biologics used for similar conditions, Bimzelx ranks highly in terms of joint outcomes and skin results. It outperforms or is comparable to most other biological/targeted synthetic DMARDs.
  • The safety profile of Bimzelx is reported as being on par with that of other biologics. Oral candidiasis emerges as one common treatment-emergent adverse event specific to this drug, but overall its adverse event profile does not significantly diverge from that of others.
  • Subgroup analyses within the studies stress that Bimzelx's efficacy remains consistent across different dosing intervals after initial maintenance without significant differences; it also shows rapid onset action regardless of previous treatment exposures, underscoring a potential advantage among patient populations.
  • Despite a relatively higher incidence rate compared to some IL inhibitors, there was no noted impact on effectiveness due to anti-drug antibodies development in patients treated with Bimzelx.

Product Monograph / Prescribing Information

Document TitleYearSource
Bimzelx (bimekizumab) Prescribing Information.2023UCB Inc., Smyrna, GA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines